{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:45:41Z","timestamp":1769042741045,"version":"3.49.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"crossref","award":["LY14H160032"],"award-info":[{"award-number":["LY14H160032"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Leukemia Research Innovative Team of Zhejiang Province","award":["2011R50015"],"award-info":[{"award-number":["2011R50015"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1097\/md.0000000000022642","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T19:52:32Z","timestamp":1601495552000},"page":"e22642","source":"Crossref","is-referenced-by-count":3,"title":["Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug"],"prefix":"10.1097","volume":"99","author":[{"given":"Xuzhao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiefeng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"R1-20230103","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00277-016-2742-7","article-title":"Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents\u2019 era","volume":"95","author":"Tsukune","year":"2016","journal-title":"Ann Hematol"},{"key":"R2-20230103","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/0366-6999.174508","article-title":"Efficacy and safety of bortezomib in multiple myeloma patients with hepatitis B: a multicenter retrospective study","volume":"129","author":"Lu","year":"2016","journal-title":"Chin Med J (Engl)"},{"key":"R3-20230103","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00277-017-3188-2","article-title":"High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin's lymphoma in China","volume":"97","author":"Wang","year":"2018","journal-title":"Ann Hematol"},{"key":"R4-20230103","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br J Haematol"},{"key":"R5-20230103","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/bjc.2013.225","article-title":"Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumors","volume":"108","author":"Ling","year":"2013","journal-title":"Br J Cancer"},{"key":"R6-20230103","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/annonc\/mdr142","article-title":"Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection","volume":"23","author":"Mya","year":"2012","journal-title":"Ann Oncol"},{"key":"R7-20230103","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4318\/tjg.2010.0087","article-title":"Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma","volume":"21","author":"Beysel","year":"2010","journal-title":"Turk J Gastroenterol"},{"key":"R8-20230103","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3960\/jslrt.52.67","article-title":"Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report","volume":"52","author":"Tanaka","year":"2012","journal-title":"J Clin Exp Hematopathol"},{"key":"R9-20230103","doi-asserted-by":"crossref","first-page":"964082","DOI":"10.1155\/2014\/964082","article-title":"Bortezomib induced hepatitis B reactivation","volume":"2014","author":"Hussain","year":"2014","journal-title":"Case Rep Med"},{"key":"R10-20230103","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/imj.12180","article-title":"Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B","volume":"43","author":"Goldberg","year":"2013","journal-title":"Intern Med J"},{"key":"R11-20230103","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1128\/AAC.01101-09","article-title":"Bortezomib inhibits hepatitis B virus replication in transgenic mice","volume":"54","author":"Bandi","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20230103","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among nortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncolo"},{"key":"R13-20230103","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/10428194.2011.610013","article-title":"High prevalence of hepatitis B virus infection in multiple myeloma","volume":"53","author":"Huang","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R14-20230103","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJM198102123040702","article-title":"Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis","volume":"304","author":"Lam","year":"1981","journal-title":"N Engl J Med"},{"key":"R15-20230103","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5045\/br.2015.50.1.51","article-title":"HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT","volume":"50","author":"Gu","year":"2015","journal-title":"Blood Res"},{"key":"R16-20230103","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3109\/10428194.2014.941833","article-title":"Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant","volume":"56","author":"Li","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R17-20230103","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bbmt.2017.01.005","article-title":"Impact of hepatitis B core antibody seropositivity on the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"23","author":"Vama","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R18-20230103","doi-asserted-by":"crossref","first-page":"eaau7130","DOI":"10.1126\/sciadv.aau7130","article-title":"Restriction of hepatitis B virus replication by c-Abl-induced proteasomal degradation of the viral polymerase","volume":"5","author":"Hou","year":"2019","journal-title":"Sci Adv"},{"key":"R19-20230103","first-page":"837","article-title":"Inhibition of hepatitis B virus production in vitro by proteasome inhibitor MG132","volume":"60","author":"Wang","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"R20-20230103","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.gastro.2006.12.001","article-title":"Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance","volume":"132","author":"Hsu","year":"2007","journal-title":"Gastroenterology"},{"issue":"(suppl 1)","key":"R21-20230103","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/liv.13006","article-title":"The prognosis and management of inactive HBV carriers","volume":"36","author":"Invernizzi","year":"2016","journal-title":"Liver Int"},{"key":"R22-20230103","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","article-title":"Durability of spontaneous and treatment-related loss of hepatitis B s antigen","volume":"18","author":"Alawad","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R23-20230103","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/cancers11111819","article-title":"Reactivation of hepatitis B virus in patients with multiple myeloma","volume":"11","author":"Tsukune","year":"2019","journal-title":"Cancer"},{"key":"R24-20230103","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.gene.2018.11.041","article-title":"Toll-like receptor 9 polymorphisms and hepatitis B virus clearance in Moroccan chronic carriers","volume":"687","author":"Chihab","year":"2019","journal-title":"Gene"},{"key":"R25-20230103","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/jmv.25394","article-title":"Association between miRNA-146a rs2910164\u200a(G\/C) polymorphism with the susceptibility to chronic HBV infection and spontaneous viral clearance in an Iranian population","volume":"91","author":"Khanizadeh","year":"2019","journal-title":"J Med Virol"},{"key":"R26-20230103","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.micpath.2019.01.008","article-title":"Association between Interleukin-21 and Interleukin-21 receptor gene polymorphisms with susceptibility to chronic hepatitis B virus infection and HBV spontaneous clearance in Iranian population","volume":"128","author":"Shoraka","year":"2019","journal-title":"Microb Pathog"},{"key":"R27-20230103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2019.09.002","article-title":"Host genetic background affects the course of infection and treatment response in patients with chronic hepatitis B","volume":"120","author":"Rybicka","year":"2019","journal-title":"J Clin Virol"},{"key":"R28-20230103","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2019.08.024","article-title":"TNF-(\/IFN-( profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection","volume":"72","author":"Wang","year":"2020","journal-title":"J Hepatol"},{"key":"R29-20230103","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided pegininterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"R30-20230103","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1128\/JVI.78.9.4566-4572.2004","article-title":"Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBX-dependent manner","volume":"78","author":"Zhang","year":"2004","journal-title":"J Virol"},{"key":"R31-20230103","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"R32-20230103","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0002-9343(74)90164-8","article-title":"Familial myeloma. Report of eight families and a study of serum proteins in their relatives","volume":"57","author":"Maldonado","year":"1974","journal-title":"Am J Med"},{"key":"R33-20230103","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ejca.2005.11.033","article-title":"Familial risks and temporal incidence trends of multiple myeloma","volume":"42","author":"Altieri","year":"2006","journal-title":"Eur J Cancer"},{"key":"R34-20230103","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMc081677","article-title":"Familial myeloma","volume":"359","author":"Camp","year":"2008","journal-title":"N Engl J Med"},{"key":"R35-20230103","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ng.993","article-title":"Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk","volume":"44","author":"Broderick","year":"2012","journal-title":"Nat Genet"},{"key":"R36-20230103","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ng.2733","article-title":"Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk","volume":"45","author":"Chubb","year":"2013","journal-title":"Nat Genet"},{"key":"R37-20230103","doi-asserted-by":"crossref","first-page":"12050","DOI":"10.1038\/ncomms12050","article-title":"Genome-wide association study identifies multiple susceptibility loci for multiple myeloma","volume":"7","author":"Mitchell","year":"2016","journal-title":"Nat Commun"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T20:49:07Z","timestamp":1672778947000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022642"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":37,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022642","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]}}}